Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193186 | 0.92 | MAPK14 (0.61) | MAPK14PPARDPPARAALOX5ROCK1 | |
| SCHEMBL6086123 | 0.89 | MAPK14 (0.54) | MAPK14PPARDPPARAALOX5ROCK1 | |
| SCHEMBL6100496 | 0.86 | ALOX5 (0.61) | MAPK14PPARDPPARAALOX5ROCK1 | |
| SCHEMBL9194734 | 0.85 | ROCK1 (0.54) | MAPK14PPARDPPARAALOX5ROCK1 | |
| SCHEMBL6098412 | 0.84 | PPARD (0.49) | MAPK14PPARDPPARAALOX5ROCK1 | |
| SCHEMBL3195439 | 0.83 | PPARG (0.52) | PPARDPPARANPC1MAOBPPARG | |
| SCHEMBL2828419 | 0.82 | FFAR1 (0.63) | MAPK14PPARDPPARA | |
| SCHEMBL6192092 | 0.81 | HTR6 (0.59) | MAPK14SMN1; SMN2ALOX5NPC1MEN1 | |
| SCHEMBL5894379 | 0.81 | HDAC8 (0.56) | MAOBPPARGHDAC3HDAC1HDAC2 | |
| SCHEMBL5734440 | 0.81 | ROCK1 (0.58) | PPARDPPARAALOX5ROCK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1325490-C | Process for preparing high purity hydroxyindolylacetylglyoxylamides | ELBION AG (DE) | 2007-07-11 | — | — | CN | claimed |
| US-7122674-B2 | Process for preparing high-purity hydroxyindolylglyoxylamides | ELBION AG (DE) | 2006-10-17 | — | — | US | claimed |
| CN-1671692-A | Method for producing highly pure hydroxy indolyl glyoxylic acid amides | ELBION AG (DE) | 2005-09-21 | — | — | CN | claimed |
| EP-1525197-A1 | METHOD FOR PRODUCING HIGHLY PURE HYDROXY INDOLYL GLYOXYLIC ACID AMIDES | Elbion AG (DE) | 2005-04-27 | — | — | EP | claimed |
| US-20040063939-A1 | Process for preparing high-purity hydroxyindolylglyoxylamides | ELBION AG (DE) | 2004-04-01 | — | — | US | claimed |
| WO-2004013127-A1 | METHOD FOR PRODUCING HIGHLY PURE HYDROXY INDOLYL GLYOXYLIC ACID AMIDES | ELBION AG (DE) | 2004-02-12 | — | — | WO | claimed |
| CN-1325490-C | Process for preparing high purity hydroxyindolylacetylglyoxylamides | ELBION AG (DE) | 2007-07-11 | — | — | CN | disclosed |
| US-7129250-B2 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2006-10-31 | — | — | US | disclosed |
| US-7122674-B2 | Process for preparing high-purity hydroxyindolylglyoxylamides | ELBION AG (DE) | 2006-10-17 | — | — | US | disclosed |
| CN-1671692-A | Method for producing highly pure hydroxy indolyl glyoxylic acid amides | ELBION AG (DE) | 2005-09-21 | — | — | CN | disclosed |
| EP-1525197-A1 | METHOD FOR PRODUCING HIGHLY PURE HYDROXY INDOLYL GLYOXYLIC ACID AMIDES | Elbion AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-11-04 | — | — | US | disclosed |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS INC. (CA) | 2004-05-27 | — | — | US | disclosed |
| US-20040063939-A1 | Process for preparing high-purity hydroxyindolylglyoxylamides | ELBION AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004013127-A1 | METHOD FOR PRODUCING HIGHLY PURE HYDROXY INDOLYL GLYOXYLIC ACID AMIDES | ELBION AG (DE) | 2004-02-12 | — | — | WO | disclosed |
| EP-1283836-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001087887-A2 | NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063939-A1 | Process for preparing high-purity hydroxyindolylglyoxylamides | HAAO, HPD, GRHPR | MAPK14 3858/4885SMN1; SMN2 4796/4885PPARD 4660/4885 |
| US-20040220202-A1 | Neuroprotective and anti-proliferative compounds | NLN, MKI67, BDNF | MAPK14 839/4885SMN1; SMN2 21/4885PPARD 526/4885 |
| US-20040102467-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NLN, BDNF | MAPK14 824/4885SMN1; SMN2 22/4885PPARD 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.